Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

147.87 -1.41 (-0.95%)

Streaming Delayed Price Updated: 10:22 AM EDT, Sep 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

99 100 Next >

Merck Plots $10 Billion Takeover Of COPD Drugmaker Verona Pharma ↗

July 09, 2025

The takeover target just launched its first drug last summer. Shares have mostly trended higher since.

Via Investor's Business Daily

Topics Government

Merck To Acquire Verona For $10B In Bid To Expand Cardio-Pulmonary Pipeline ↗

July 09, 2025

Merck will acquire Verona for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion.

Via Stocktwits

Topics Government

Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade

July 09, 2025

From Merck & Co., Inc.

Via Business Wire

Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Merck (NYSE:MRK)

July 08, 2025

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Merck (NYSE:MRK) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025

July 08, 2025

From Merck & Co., Inc.

Via Business Wire

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

July 07, 2025

Via Investor Brand Network

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

July 07, 2025

EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:REGN),(NASDAQ:VRTX),(OTCQX:RHHBY),(NYSE:MRK) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗

July 07, 2025

Via The Motley Fool

Topics Stocks

Trump's 'Big, Beautiful Bill' Hands $5 Billion Win To Big Pharma: Report ↗

July 04, 2025

Trump's $3.3 trillion domestic agenda bill, passed by the House on Thursday, includes a significant victory for pharmaceutical companies .

Via Benzinga

Topics Government

2 S&P 500 Stocks with Promising Prospects and 1 to Question

July 04, 2025

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,...

Via StockStory

Topics Stocks

Uncover the latest developments among S&P500 stocks in today's session. ↗

July 03, 2025

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday.

Via Chartmill

AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment ↗

July 03, 2025

Via Benzinga

What's going on in today's session: S&P500 gap up and gap down stocks ↗

July 03, 2025

Wondering which stocks are making significant price gaps? Explore the S&P500 index on Thursday to find the gap up and gap down stocks in today's session.

Via Chartmill

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗

July 03, 2025

Via Benzinga

Merck's Hypertension Drug On FDA Fast Track For Label Expansion ↗

July 02, 2025

Merck's Winrevair gains FDA priority review for PAH label update after ZENITH trial shows major reduction in serious events and strong clinical impact.

Via Benzinga

FDA Grants Priority Review for WINREVAIR™ (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial

July 02, 2025

From Merck & Co., Inc.

Via Business Wire

MERCK & CO. INC. (NYSE:MRK) – A Strong Value Candidate in Healthcare ↗

July 02, 2025

MERCK & CO. (NYSE:MRK) is an undervalued pharmaceutical stock with strong profitability, a healthy balance sheet, and a reliable dividend, making it a candidate for value investors.

Via Chartmill

Dogs Of The Dow: How You Can Get Dividend Stocks With Yields Up To 6.3% ↗

July 01, 2025

The Dow Jones Industrial Average stocks average a 2% dividend yield through the first six months of 2025. Here are the top yields.

Via Benzinga

Topics Stocks

Dow Jones 2025 First Half Scoreboard: Top 10 Winners, Losers — Where Do Nvidia, Apple Stock Rank? ↗

July 01, 2025

The Dow Jones Industrial Average was up around 4% in the first half of 2025 with a large majority of the 30 stocks positive.

Via Benzinga

Topics Stocks

Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29

July 01, 2025

From Merck & Co., Inc.

Via Business Wire

July 01, 2025

Via The Motley Fool

Topics Artificial Intelligence ETFs Stocks

Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? ↗

June 30, 2025

The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.

Via Investor's Business Daily

Peering Into Merck & Co's Recent Short Interest ↗

June 30, 2025

Via Benzinga

1 Profitable Stock to Consider Right Now and 2 to Think Twice About

June 30, 2025

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Via StockStory

3 Absurdly Cheap Stocks Ready for a Breakout ↗

June 28, 2025

All three stocks are poised to go higher.

Via The Motley Fool

RFK Jr's CDC Panel Recommends Merck's RSV Shot For Infants ↗

June 27, 2025

CDC panel backs Merck's Enflonsia for RSV prevention in infants; FDA-approved therapy reduced hospitalizations by 84% in clinical trials.

Via Benzinga

CDC Vaccine Panel Overhauled by RFK Jr. Votes To Drop Mercury Preservative, Critics Sound Alarm ↗

June 26, 2025

The panel also voted to recommend Merck’s RSV antibody drug Enflonsia for newborns whose mothers didn’t receive prenatal protection.

Via Stocktwits

5 Biotech Stocks with Highly Anticipated Pending Results ↗

June 26, 2025

Via Stocktwits

Topics Intellectual Property

Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise ↗

June 26, 2025

Elanco upgraded to Outperform by William Blair as pipeline gains traction and EMA backs Zenrelia ahead of expected Q3 approval.

Via Benzinga

ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season

June 26, 2025

From Merck & Co., Inc.

Via Business Wire

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.